Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Unusual Options Activity: EXPE, ALAB and Others Attract Market Bets, EXPE V/OI Ratio Reaches 95.2
EST Oct 9th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Express News | Amgen Inc : JP Morgan Raises Target Price to $300 From $290
Zenas Started at Buy by Four Banks on Lead Drug Potential
Obesity Drugs Seen Costing Medicare $35 Billion Through 2034
Obesity Drug Coverage Could Boost Spending By $35B Through 2034
TEVA Applications for Prolia Biosimilar Accepted by FDA, EMA
Amgen Analyst Ratings
Barclays Keeps Their Hold Rating on Amgen (AMGN)
Barclays Adjusts Price Target on Amgen to $315 From $300, Maintains Equalweight Rating
DBS Maintains Amgen(AMGN.US) With Buy Rating
Amgen (AMGN) Rose Owing To The Announcement Of Promising Data For Its Novel Medication
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
U.S. Tweaks 2025 Medicare Price Negotiation Process
Amgen (NASDAQ:AMGN) Has A Somewhat Strained Balance Sheet
Eli Lilly and Co (LLY.US) explores new uses for 'weight-loss miracle drug' Zepbound, aiming to reduce the incidence of high-risk populations such as diabetes.
eli lilly and co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Express News | La La Anthony Partners With Amgen to Share Candid, Behind-the-Scenes Look at How Plaque Psoriasis Affects Her Life
(AMGN) - Analyzing Amgen's Short Interest
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report